Collaboration will enable doctor’s office capillary blood draws, sample prep, and lab transport for advanced blood tests without phlebotomy

PLEASANTON, CA, USA, September 22, 2020 /EINPresswire.com/ -- Sandstone Diagnostics, Inc. and Myriad Genetics, Inc. (NASDAQ:MYGN), have entered into a Collaborative Development Agreement to construct a system enhancing the ease, safety, and effectiveness of point-of-care blood collection.

Sandstone will develop an integrated device enabling point-of-care, high-quality serum collection from patients in the doctor’s office, with onboard sample preparation using its Torq™ zero delay centrifuge technology for stable transportation to a centralized laboratory. Myriad will validate the resulting product's efficacy with its Vectra^® advanced blood test that objectively measures inflammation caused by rheumatoid arthritis.

Sandstone has independently developed a new version of its portable, battery-operated centrifuge: the Torq ZDrive MR enabling decentralized centrifugation of small volume capillary blood samples.

Sandstone Diagnostics is a diagnostic and device biotech company located in Pleasanton, CA. Myriad Genetics, headquartered in Salt Lake City, is a global leader in molecular diagnostics and precision medicine dedicated to transforming and improving lives by discovering and delivering tests across major diseases.

Greg Sommer
Sandstone Diagnostics, Inc.
+1 734-476-2111
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.